FOLH1 and prostate carcinoma: Nonetheless, the present study is the first to investigate the use of CAR-modified NK-92 cells against PCa; in particular, we aimed at modifying NK-92 cells to express a PSMA-specific CAR, and thus to convert them into a prostate cancer-specific therapeutic tool characterized by improved efficacy.